UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2025

Commission File Number: **001-42128**

Telix Pharmaceuticals Limited

(Translation of registrant's name into English)

55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On January 13, 2025, Telix Pharmaceuticals Limited (the "Company") filed with the Australian Securities Exchange (the "ASX") an announcement (the "Announcement") captioned "TLX to Acquire Next-Gen Therapeutics and Biologics Platform," a copy of which is attached to this Form 6-K as Exhibit 99.1.

Attached as Exhibit 99.2 is a presentation the Company filed with the ASX on January 13, 2025 in connection with the Announcement.

99.1	Announcement - January 13, 2025.
99.2	Presentation - January 13, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Telix Pharmaceuticals Limited

Date: January 13, 2025

By: /s/ Genevieve Ryan

Name: Genevieve Ryan
Title: Company Secretary

Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX ANNOUNCEMENT

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 13 January 2025. Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities.

This transaction adds a pipeline of early-stage drug candidates against high-value targets including DLL3[1] and integrin αvβ6[2], as well as several other novel targets in discovery stage. These next generation drug candidates fit synergistically with Telix's therapeutics pipeline, enabling expansion to future therapy areas with unmet clinical need. The acquired intellectual property utilizes small engineered antibody formats that enable highly specific cancer targeting, combined with fast tumor uptake and blood clearance. This technology has the potential to be highly effective for imaging and treating tumors with a broad range of radioisotopes, with alpha emitters of particular interest.

The transaction also includes a state-of-the-art research facility in California, staffed by a talented team of discovery, protein engineering and radiopharmaceutical development experts. Together, these assets will provide Telix with further in-house capabilities in antibody engineering and preclinical development, as well as a novel biologics platform to create the next generation of Telix precision medicine and therapeutic products, beyond the current clinical-stage pipeline.

Richard Valeix, Chief Executive Officer, Therapeutics, Telix, said, "The combination of a proprietary drug discovery platform, pipeline of promising theranostic assets and a talented team of subject matter experts will enhance Telix's research and innovation capability now and into the future. This acquisition will enable Telix to explore new disease areas with state-of-the-art radiotherapeutic technology."

Dr. Anna M. Wu, Co-Founder and Board Member, ImaginAb, added, "As the radiopharmaceutical sector gains momentum there is a significant need for targeting agents to be more selective, deliver less off-target radiation, and better match the pharmacology and radiobiology of a given radionuclide. The team's deep expertise in antibody engineering and the resulting development of a valuable, proprietary platform technology has led to clinical proof-of-concept. Telix is the right partner to unlock the future therapeutic potential of this platform."

Transaction details

Telix will acquire these assets through an asset purchase agreement with a concurrent technology license agreement to be signed at closing. The purchase price for the transaction is US$45 million

[1] Delta-like ligand 3, a cell surface protein overexpressed in high-grade neuroendocrine tumors and small cell lung cancer (SCLC).

(AU$73 million)[3], comprised of US$10 million in cash and US$31 million in equity at closing, and a deferred payment of up to US$4 million in equity at the conclusion of a 15-month indemnity period.
Upon achievement of specific key development and commercial milestones, Telix will pay up to a total of US$185 million (AU$299 million), a portion of which may be paid in cash or equity at Telix's election[4]. Royalties are also payable on net sales in the low single digits on a limited number of platform and early-stage products after the first four products have been developed, as well as single-digit sublicense fees, as applicable.

Telix will issue ordinary shares to ImaginAb within its Listing Rule 7.1 placement capacity as consideration for the acquisition. Upfront equity consideration will be subject to voluntary escrow (lock-up/leak-out) restrictions with equal tranches being released from escrow 60, 90 and 120 days after closing. Completion of the transaction is subject to customary conditions, including regulatory approvals and other third-party consents. Telix cannot guarantee this transaction will close in any specific timeframe or on the terms summarized here, if at all.

About ImaginAb, Inc.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of radiopharmaceutical and imaging agent products. These patented products contain engineered antibodies that maintain the specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available positron emission tomography (PET) and optical imaging technology, these novel targeting agents are able to bind specifically to cell surface targets.

Following closing of its transaction with Telix Pharmaceuticals, ImaginAb, Inc. will be focused on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within immunotherapy clinical trials, primarily in oncology.

Jefferies LLC and Stifel, Nicolaus & Company, Incorporated served as financial advisors to ImaginAb on the transaction.

Disclosures

Telix Managing Director and Group Chief Executive Officer, Dr. Christian Behrenbruch, is a non-affiliated shareholder of ImaginAb, holding less than 1% of its capital stock as his only interest in the company. Dr. Behrenbruch abstained from the transaction process and the Telix Board's approval of the arm's length acquisition. Dr. Behrenbruch has voluntarily elected, via a binding undertaking, to donate any enrichment from the transaction as the result of his shareholding to charity.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Telix's lead imaging product, gallium-68 (^{68}Ga) gozetotide injection (also known as ^{68}Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug

[2] Integrin αvβ6 is a cell surface protein overexpressed during wound healing and in cancer.
[3] All references to AUD have been converted at the AUD/USD exchange rate of 1.614.

Administration (FDA)[5], by the Australian Therapeutic Goods Administration (TGA) [6], and by Health Canada[7]. No other Telix product has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

[4] Refer to Appendix to this announcement and Appendix 3B lodged with the ASX today for further details.
[5] Telix ASX disclosure 20 December 2021.
[6] Telix ASX disclosure 2 November 2021.

Appendix – key terms of milestone payments that may be settled in equity issuance

(a) The milestone payments that may be equity settled will be in the form of rights (Performance Rights) granted by Telix to ImaginAb, Inc. at closing.

(b) The Performance Rights will have an aggregate value of US$60 million.

(c) The Performance Rights will be issued in four tranches of US$15 million each, corresponding to the successful achievement of four separate 'Milestone Events' relating to the ongoing development and commercialization of the acquired assets.

(d) The Performance Rights will fully vest and be capable of conversion to Telix shares on the achievement of the applicable Milestone Event, or such earlier date that Telix determines. On satisfaction of the Milestone Events, Telix may elect to: (i) pay a cash amount representing the face value of the Performance Rights that have been satisfied; or (ii) satisfy the Performance Rights via the issue of Telix shares.

(e) The number of any Telix shares to be issued on satisfaction of a tranche of Performance Rights is calculated by:

(i) First, determining the face value of the tranche of Performance Rights that have been satisfied (via the occurrence of the Milestone Event by a particular time).

(ii) Second, converting that amount into AUD using the Reserve Bank of Australia conversion rate on the date that the Performance Rights are satisfied.

(iii) Third, dividing that AUD amount by the 20-day volume weighted average price of Telix shares up to the date of satisfaction of the Milestone Event.

(f) Each Performance Right will have a USD-denominated face value which will be determined at or around the time of issue of the Performance Rights. It will be the value that most-closely represents one Telix share at the time (calculated in accordance with the formula in subparagraph (e) above).

(g) Telix will apply for quotation of any shares issued on satisfaction of the Performance Rights. Any such shares will be fully paid ordinary shares and will not be subject to escrow restrictions.

(h) No Telix shares may be issued to satisfy any Performance Rights after the five-year anniversary of the issue date of the Performance Rights.

(i) The Performance Rights are not transferrable, unless the transfer is approved by Telix and the ASX.

(j) If there is a change of control of ImaginAb, Inc., Performance Rights cannot be satisfied via the issue of Telix shares and must be cash settled.

(k) If there is a change of control or delisting from the ASX of Telix, to the extent that Performance Rights have not been satisfied at the time but are subsequently satisfied, Performance Rights cannot be satisfied via the issue of Telix shares and must be cash settled.

(l) The Performance Rights will not be quoted on ASX or any other securities exchange.

(m) Holders of Performance Rights will not be entitled to participate in new issues of securities offered to holders of shares such as bonus issues and entitlement issues.

(n) The Performance Rights do not confer on the holder an entitlement to vote, except as otherwise required by law.

(o) The Performance Rights do not confer any entitlement to a dividend, whether fixed or at the discretion of Telix.

(p) The Performance Rights do not confer any right to a return of capital, whether in a winding up of Telix, upon a reduction of capital of Telix, or otherwise.

(q) The Performance Rights do not confer any right to participate in the surplus profits or assets of Telix upon a winding up of Telix.

(r) The Performance Rights and the rights and obligations of holders are governed by the laws of Victoria, Australia. Each holder irrevocably and unconditionally submits to the non-exclusive jurisdiction of the courts of Victoria and the Federal Court of Australia and any courts that may hear appeals from those courts about any proceedings in connection with the Performance Rights.

[7] Telix ASX disclosure 14 October 2022.

Telix

Acquisition of Next-generation Therapeutic Assets and Novel Biologics Technology Platform

Telix Pharmaceuticals

NASDAQ: TLX | ASX: TLX

January 2025

Disclaimer

This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchang Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website.

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Tel jurisdiction, including the United States. The information and opinions contained in this presentation are subject to change without notification. To the disclaims any obligation or undertaking to update or revise any information or opinions contained in this presentation, including any forward-looking statem result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implie completeness of the information contained or opinions expressed in this presentation.

This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that re performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "ma "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking stater uncertainties and other factors that may cause Telix's actual results, levels of activity, performance or achievements to differ materially from any future achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to t risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including r likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, mark capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate su for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; develop industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or a from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance

This presentation also contains estimates and other statistical data made by independent parties and by Telix relating to market size and other data about of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and es the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.

Telix's lead imaging product, gallium-68 (^{68}Ga) gozetotide injection (also known as ^{68}Ga PSMA-11 and marketed under the brand name Illuccix®), has be Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. No other Telix product has received a marketing

This presentation has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Telix

Transaction to acquire novel biologics platform and

Platform, pipeline, and people from ImaginAb Inc.

Transaction provides Telix with multiple IND-ready assets



1. **Platform:** a proprietary technology platform to generate unique t (therapeutic + diagnostic) engineered antibodies as radiopharma targeting agents
2. **Pipeline:** a pipeline of multiple preclinically characterized theran derived from the platform
3. **People:** a research team and facility to expand platform and pipe adding new technical competencies to Telix

Adds novel, proprietary technology to Telix's development pipeline

- Engineered antibody fragments combine the advantages of both and small molecules
- Designed to enable rapid tumor uptake and high tissue penetrati with faster clearance from blood circulation

Telix

1. Refer to ASX announcement lodged today for further details.

Deal summary

Structure:	Asset Purchase Agreement with concurrent Technology License Agreement pro exclusive and non-exclusive rights to specific patents and know-how retained b
Assets Acquired:	Platform Technology; ongoing Designated Programs; Discovery-Stage Assets; I and other similar Assets; related Seller IP, Data and Documentation.
Purchase Price:	US$45 million (AU$73 million)[1] comprised of US$10 million in cash and US$31 closing, and deferred payment of up to US$4 million in equity at conclusion of 1 period subject to set-off by Telix for indemnity claims above a defined threshold.
Contingent Future Payments:	Up to a total of US$185 million (AU$299 million) upon achievement of specific k commercial milestones (of which up to US$60 million may be paid in cash or eq Low single-digit Royalties on Net Sales of limited number of platform and early- four products have been developed, and single-digit sublicense fees, as applica
Escrow (Lock-Up):	Upfront equity subject to voluntary escrow (lock-up/leak-out) restrictions with eq released from escrow 60, 90 and 120 days after Closing.
Closing:	Standard closing conditions.

Telix

1. All references to AUD have been converted at the AUD/USD exchange rate of 1.614.
2. Refer to Appendix in ASX announcement and Appendix 3B lodged with the ASX today for further details.

Engineered antibody targeting agents offer best of

Bridging the gap between small molecules and antibodies

'Antibody fragments' have a molecular weight between full-length antibodies and smaller biologics.

This provides a powerful combination of:

- binding affinity
- tumor uptake
- internalization
- clearance from the body

Format trade-offs

	Small molecule/peptide	Engineered mAb
Time to max tumor uptake	Fast	
Blood clearance	Fast	
Tumor retention	Low	
Internalization	Less likely	

Telix

1. Kilodalton, a measure of molecular mass.
2. Monoclonal antibody.

A platform technology ideal for radiopharmaceutica

Proprietary technology to develop protein-based therapeutic agents

Advantage vs. antibodies

- Faster tumor uptake
- High tumor penetration
- Optimal (and tunable) blood clearance rate for broader range of isotopes
- Improved clearance to reduce radiation to normal tissue
- Suited to both alpha- and beta-emitting isotopes

Advantage vs. small molecules

- High affinity and targeting selectivity
- Can be modified with different chelators without impact on affinity
- Internalization and intercellular processing results in residualization of radiometals (as with full length mAbs)
- Continuous tumor accumulation over time, avoiding first pass clearance



Telix

1. ImaginAb data on file.

New pipeline of therapeutic assets

Lead compounds validate the utility of the technology platform

- The acquisition adds a pipeline of therapeutic compounds addressing commercially valuable indications with high unmet clinical need
- Multiple preclinically characterized therapeutic lead molecules against high-value targets including DLL3[1], integrin αvβ6[2], as well as a discovery pipeline
- Complements Telix's proprietary chelator platforms for use with Telix's established radioisotopes (^{177}Lu, ^{225}Ac, ^{89}Zr)



Telix

1. Delta-like ligand 3, a cell surface protein overexpressed in high-grade neuroendocrine tumors and small cell lung cancer (SCLC).
2. Integrin αvβ6 is a cell surface protein overexpressed during wound healing and in cancer.
3. Investigational new drug application.

New high-value targets: Integrin αvβ6 and DLL3

Opportunity to leverage novel theranostic mechanism of action against

Integrin αvβ6 (IAB56)

- **Highly expressed across range of cancers** with high unmet need including
  - 90%+ of ovarian cancer[1], **19k U.S. patients diagnosed p.a.**[4]
  - 90%+ of pancreatic cancer[2], **66k U.S. patients diagnosed p.a.**[4]
  - 50%+ of non-small cell lung cancer (NSCLC)[3], **187k+ U.S. patients diagnosed p.a.**[4]
- Pfizer currently conducting Phase 3 trial of αvβ6-targeting antibody-drug conjugate (ADC) in NSCLC (Sigvotatug Vedotin)

DLL3 (IA

- **Expressed in 85% of SCLC**[5]
  - **23k+ U.S. patients diagn**
  - High unmet need with 7%
- 2024 FDA approval of Amgen T-cell engager for extensive-s
- Novartis' acquisition of Mariar USD 1.75B included a pre-cli radiotherapeutic
- Recent in-licensing deals for Roche and by Ideaya

1: Ahmed et al. *Carcinogenesis*. 2002.
2: Sipos et al. *Histopathol*. 2004.
3. Elayadi et al. *Cancer Res*. 2007.
4. American Cancer Society, Key Statistics 2024.
5. Rojo et al. *Lung Cancer*. 2020.

Telix

Integrin αvβ6 targeting: Preclinical summary (IAB56

Favorable dosimetry and efficacy

- Tumor targeting demonstrated in multiple relevant tumor xenograft models
- Efficacy studies highly reproducible, demonstrating significant tumor growth inhibition
- IAB56 is highly selective for Integrin αvβ6 but does not block αvβ6 activity on healthy tissues, which could cause side effects

Pre-clinical dosimetry well below established toxicity thresholds

Organ	Dosimetry at 100mCi (Gy)	Tox Threshold (Gy)
Kidney	3.06	23
Liver	4.98	32
Spleen	2.16	40
Red marrow	0.04	2



Telix

1. ImaginAb data presented at AACR 2024.

DLL3 targeting: Preclinical summary (IAB57)[1]

Demonstrated efficacy in an unmet clinical need

- Tumor targeting demonstrated in multiple SCLC xenograft models
- IAB57 shows excellent manufacturability properties and cross-reactivity to ortholog DLL3 antigen
- IAB57 demonstrates rapid treatment response in murine xenograft models

Pre-clinical dosimetry well below established toxicity thresholds

Organ	Dosimetry at 100mCi (Gy)	Tox Threshold (Gy)
Kidney	2.43	23
Liver	5.22	32
Spleen	1.69	40
Red marrow	0.12	2



Telix

1. ImaginAb data presented at AACR 2024.

Clinical proof of concept

Demonstrates highly specific targeting of cancer with favorable pharma





- IAB2M is an engineered mAb developed as a first-in-human clinical proof of concept in this stud
- Lesions were seen within the first 24 hours after injection and uptake was seen to increase at e timepoint throughout the course of the study; demonstrating effective residualization of radiation
- IAB2M shows highly specific targeting of cancer lesions, with no salivary gland uptake and faste blood as expected

Telix

1. Pandit-Taskar et al. *J Nucl Med.* 2016.
2. Memorial Sloan Kettering Cancer Center.

Discovery platform, people and lab to bolster R&D

A faster way to develop candidates across a range of cancer indications

Rapid "concept to clinical" model

- Research and Development laboratory and team provides Telix with ability to identify, characterize and validate future therapeutic pipeline assets
- Adds further in-house capabilities in modern protein engineering techniques and preclinical candidate development and validation
- Bioreactor for engineered antibody production, and *in vitro* and cell-based assays for characterization
- Ability to conduct pre-clinical imaging and therapy studies in house, accelerating the path to clinical studies and supporting Telix's broad pipeline development activity

Protein characterization core lab a

Telix

Transaction summary

Reinforcing leadership position in theranostics

Platform

Proprietary technology to generate engineered antibody targeting agents

- Bespoke radiopharmaceuticals balancing tumor uptake and blood clearance
- Rapid development of new assets with optimized therapeutic profile
- In-house asset creation with full ownership of intellectual property

Pipeline

Opportunity to leverage theranostic MoA[1] against high-value targets

- Adds assets against clinically-validated targets; DLL3 and integrin αvβ6
- Lifecycle management opportunities to repurpose existing antibodies
- Additional research pipeline candidates against multiple antibody-drug conjugate (ADC) targets

New ca exis

- Compl manuf includi ARTM
- Fits wi includi
- R&D fa serves targeti

Telix

1. Mechanism of action.

Contact details:

Kyahn Williamson

SVP Investor Relations and
Corporate Communication

kyahn.williamson@telixpharma.com

Telix